Alexander Ashby
Overview
Explore the profile of Alexander Ashby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olechowski B, Dalton R, Khanna V, Ashby A, Vavyla M, Mariathas M, et al.
Cardiovasc Ther
. 2018 Apr;
36(4):e12433.
PMID: 29682911
Introduction: There is potential value in testing individual response to P2Y12 inhibitors to predict ischemic and bleeding risk in patients undergoing percutaneous coronary intervention. The aims of this study were:...
2.
Olechowski B, Khanna V, Mariathas M, Ashby A, Dalton R, Nordon I, et al.
Platelets
. 2017 Dec;
30(2):190-198.
PMID: 29227173
The role of platelets in ischaemic events is well established. Aspirin represents the default antiplatelet and blocks the metabolism of arachidonic acid (AA) at the cyclo-oxygenase enzyme (COX). AA is...
3.
Olechowski B, Ashby A, Mariathas M, Khanna V, Mahmoudi M, Curzen N
Expert Rev Cardiovasc Ther
. 2016 Nov;
15(1):35-46.
PMID: 27892731
Platelets play a key role in pathogenesis of atherothrombosis. Activated platelets initiate thrombus formation. Antiplatelet therapy (APT) modifies these properties. APT involves aspirin. The existence of 'aspirin resistance' is reported...
4.
Olechowski B, Ashby A, Sambu N, Mahmoudi M, Curzen N
Case Rep Med
. 2016 Nov;
2016:2096181.
PMID: 27799942
Patients after percutaneous coronary intervention (PCI) with stent implantation and functional hyporesponsiveness to PY inhibitors are at higher risk of ischaemic events, particularly stent thrombosis (ST). It is currently not...